Table 1 Characteristics of intention-to-treat analysis population at baseline examination (T0).

N

n = 26

n = 28

Female Sex^#

11 (42.3%)

16 (57.1%)

Age (years)* [n_miss = 0]

51.6 (11.9 ± SD)

52.4 (9.8 ± SD)

Weeks between SARS-CoV-2 infection and baseline examination ^† [n_miss = 0]

101.3 (91.6–114.6)

99.1 (95.1–112.6)

Weeks between baseline and follow-up examination ^† [n_miss = 0]

13.4 (13.1–14.3)

12.9 (12.1–14.9)

SARS-CoV-2 re-infection before baseline examination^# [n_miss = 2]

5 (20.8%)

10 (35.7%)

Sport activity before SARS-CoV-2 infection^# [n_miss = 2]

21 (87.5%)

21 (75.0%)

Performance of training after SARS-CoV-2 infection ^# [n_miss =3 ]

19 (79.2%)

19 (70.4%)

Former sport activities^# [n_miss = 6]

 Regular

17 (68.0%)

11 (47.8%)

 Occasional

5 (20.0%)

9 (39.1%)

 Rare

3 (12.0%)

1 (4.4%)

 Never

0 (0.0%)

2 (8.7%)

Former competitive athletes ^# [n_miss = 2]

7 (29.2%)

6 (21.4%)

Smoking status^# [n_miss = 0]

 Current

2 (7.7%)

4 (14.3%)

 Former

9 (34.6%)

10 (35.7%)

 Never

15 (57.7%)

14 (50.0%)

Previous or current comorbidities

 Arterial hypertension ^# [n_miss = 0]

4 (15.4%)

6 (21.4%)

 Diabetes mellitus Type II^# [n_miss = 0]

1 (3.9%)

0 (0.0%)

 Dyslipoproteinemia^# [n_miss = 0]

1 (3.9%)

2 (7.1%)

 Asthma and/or allergy^# [n_miss = 0]

11 (42.3%)

17 (60.7%)

 Cardiovascular disease^# [n_miss = 0]

4 (15.4%)

8 (28.6%)

 Metabolic disease^# [n_miss = 0]

3 (11.5%)

3 (10.7%)

 Other lung disease^# [n_miss = 0]

2 (7.7%)

6 (21.4%)

 Neurological disease^# [n_miss = 0]

1 (3.9%)

2 (7.1%)

 Mental disease^# [n_miss = 0]

6 (23.1%)

2 (7.1%)

 Gastrointestinal disease^# [n_miss = 0]

2 (7.7%)

4 (14.3%)

 Orthopaedic disease^# [n_miss = 0]

14 (53.9%)

13 (46.4%)

 Cancer

2 (7.7%)

0 (0.0%)

 Other disease^# [n_miss = 0]

7 (26.9%)

4 (14.3%)

Surgery^# [n_miss = 0]

14 (53.9%)

20 (71.4%)

Accident^# [n_miss = 0]

4 (15.4%)

8 (28.6%)

Hospitalization^# [n_miss = 0]

14 (53.9%)

12 (42.9%)